mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2013-2441mrj-529Research ArticleСтатьиArticlesЧасть II. Терапия ревматоидного артритаPart II. Therapy for rheumatoid arthritisДемидоваН. В.DemidovaNatalia Viktorovnanatasha-demidova@mail.ruФГБУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» РАМН, МоскваРоссияV.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, MoscowRussian Federation20131012201374№4 (2013)7173Copyright © Демидова Н.В., 20132013Демидова Н.В.Demidova N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/529

23–25 мая 2013 г. в Каролинском институте (Стокгольм, Швеция) при поддержке Компании MSD была проведена Клиническая обсервационная программа для врачей-ревматологов, в которой приняли участие известные ревматологи и ведущие специалисты института проф. R. van Vollenhoven, проф. L. Klareskog, д-р. E. af Klint, д-р. C. Carlens. В докладах и на интерактивных сессиях обсуждались проблемы ревматоидного артрита (РА), в том числе раннего РА (этиология, патогенез, лечение), регистры пациентов с ревматическими заболеваниями, УЗИ-диагностика воспалительных заболеваний опорно-двигательного аппарата, биологическая терапия ревматических заболеваний, организация работы исследовательской иммунологической лаборатории, поликлинического отделения и отделения дневного стационара в ревматологической клинике. Программу посетили врачи из различных стран Европы (Швеция, Германия, Франция, Россия, Испания, Греция и др.).  Ниже представлен обзор материалов Клинической обсервационной программы.

On 23–25 May 2013, the Karolinska Institute (Stockholm, Sweden) with the support of MSD company held a meeting on a Clinical Observational Program for rheumatologists, which was attended by the well-known rheumatologists and leading specialists of the Institute Prof. R. van Vollenhoven, Prof. L. Klareskog, Dr. E. af Klint, and Dr. C. Carlens. The reports and interactive sessions discussed the problems of rheumatoid arthritis (RA), including early RA (pathology, pathogenesis, and treatment), registers of with rheumatic diseases; ultrasound diagnosis of inflammatory locomotor diseases; biological therapy for rheumatic diseases; organization of work in the research immunological laboratory, outpatient/day hospital units of a rheumatology clinic. The Program was also attended by physicians from different European countries (Sweden, Germany, Russia, Spain, Greece, etc.). Below is given an overview of the proceedings of the Clinical Observational Program.

ревматоидный артритплевритпаренхиматозные болезниантитела к циклическому цитруллинированному пептидуrheumatoid arthritispleurisyparenchymal diseasesanticyclic citrulinated peptide antibodiesReferences<div><p>Rezaei Н, Saevarsdottir S, Geborek P et al. Evaluation of hand bone loss by digital X-ray radiogrammetry as a complement to clinical and radiographic assessment in early rheumatoid arthritis: results from the SWEFOT trial. BMC Musculoskelet Disord. 2013;14:79. DOI: 10.1186/1471-2474-14-79.</p><p>Saevarsdottir S, Wallin H, Seddighzadeh M et al.; SWEFOT Trial Investigators Group. Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. Ann Rheum Dis. 2011;70(3):469–75. DOI: 10.1136/ard.2010.139212. Epub 2010 Dec 13.</p><p>De Vries-Bouwsta JK, Goekoop-Ruieterman Y, van Zeden D et al. A comparison of clinical and radiological outcomes of four treatment strategies for early rheumatoid arthritis: results of the BeST trial. Ann Rheum Dis. 2004;63 Suppl l:S58.</p><p>Kavanaugh A, Fleischmann RM, Emery P et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis. 2013;72(1):64–71. DOI: 10.1136/annrheumdis-2011-201247. Epub 2012 May 5.</p><p>Horslev-Petersen K, Hetland ML, Junker P et al.; OPERA study-group. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. Ann Rheum Dis. 2013 Mar 7. DOI: http://dx.doi.org/10.1136%2Fannrheumdis-2012-202735.</p><p>Haraoui B. Is there a rationale for switching from one anti-tumor necrosis factor agent to another? J Rheumatol. 2004;31(6):1021–2.</p><p>Van Vollenhoven R, Harju A, Brannemark S et al. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor α blockers can make sense. Ann Rheum Dis. 2003;62(12):1195–8.</p><p>Van Vollenhoven R. Switching between anti‐tumour necrosis factors: trying to get a handle on a complex issue. Ann Rheum Dis. 2007;66(7):849–51. DOI: http://dx.doi.org/10.1136%2Fard.2007.069872.</p></div><br /><div><p>Rezaei Н, Saevarsdottir S, Geborek P et al. Evaluation of hand bone loss by digital X-ray radiogrammetry as a complement to clinical and radiographic assessment in early rheumatoid arthritis: results from the SWEFOT trial. BMC Musculoskelet Disord. 2013;14:79. DOI: 10.1186/1471-2474-14-79.</p><p>Saevarsdottir S, Wallin H, Seddighzadeh M et al.; SWEFOT Trial Investigators Group. Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. Ann Rheum Dis. 2011;70(3):469–75. DOI: 10.1136/ard.2010.139212. Epub 2010 Dec 13.</p><p>De Vries-Bouwsta JK, Goekoop-Ruieterman Y, van Zeden D et al. A comparison of clinical and radiological outcomes of four treatment strategies for early rheumatoid arthritis: results of the BeST trial. Ann Rheum Dis. 2004;63 Suppl l:S58.</p><p>Kavanaugh A, Fleischmann RM, Emery P et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis. 2013;72(1):64–71. DOI: 10.1136/annrheumdis-2011-201247. Epub 2012 May 5.</p><p>Horslev-Petersen K, Hetland ML, Junker P et al.; OPERA study-group. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. Ann Rheum Dis. 2013 Mar 7. DOI: http://dx.doi.org/10.1136%2Fannrheumdis-2012-202735.</p><p>Haraoui B. Is there a rationale for switching from one anti-tumor necrosis factor agent to another? J Rheumatol. 2004;31(6):1021–2.</p><p>Van Vollenhoven R, Harju A, Brannemark S et al. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor α blockers can make sense. Ann Rheum Dis. 2003;62(12):1195–8.</p><p>Van Vollenhoven R. Switching between anti‐tumour necrosis factors: trying to get a handle on a complex issue. Ann Rheum Dis. 2007;66(7):849–51. DOI: http://dx.doi.org/10.1136%2Fard.2007.069872.</p></div><br />

The authors declare that there are no conflicts of interest present.